Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERALD-3 in localized hepatocellular carcinoma
CTR20221993Phase 3Active
- Sponsor
- MedImmune
- Start
- Jan 2023
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of durvalumab, tremelimumab, lenvatinib in hepatocellular carcinoma (HCC), sponsored by MedImmune. Started Jan 2023; status: active.
02
Drugs
durvalumabtremelimumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20221993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221993.